This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2016 by Pharmacosmos A/S
Max Neeman
Information provided by (Responsible Party):
Pharmacosmos A/S Identifier:
First received: June 26, 2013
Last updated: March 1, 2016
Last verified: February 2016
The primary purpose of the study is to evaluate the effect of IV iron isomaltoside 1000 compared with placebo on Hb in first-time female donors with p-ferritin below 30 µg/L

Condition Intervention Phase
Iron-deficiency Drug: Iron isomaltoside 1000 (Monofer®) Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-Deficient Blood Donors

Resource links provided by NLM:

Further study details as provided by Pharmacosmos A/S:

Primary Outcome Measures:
  • Change in Hb concentration [ Time Frame: From baseline and until t= 6 months ]
    The primary endpoint is to measure and compare the change in Hb concentration from baseline to right before the third blood donation in the two study arms

Secondary Outcome Measures:
  • Change in Hb concentration [ Time Frame: From baseline and until t=3 months ]
    Change in Hb concentrations from baseline to right before second donation

  • Ability to complete 3 blood donations [ Time Frame: From baseline and until t=6 months ]
    Number of subjects who cannot complete three donations due to low Hb

  • Change in p-iron [ Time Frame: From baseline and until week 12 ]
  • Change in fatigue symptoms [ Time Frame: From baseline and until week 12 ]
  • Exercise tolerance [ Time Frame: From baseline to week 3 ]
    Change in exercise tolerance from baseline to 3 weeks after baseline measured by a two-step test on bike

  • Number of adverse drug reactions [ Time Frame: From screening and until t= 6 months ]
  • Change in p-ferritin [ Time Frame: From baseline and until week 12 ]
  • Change in Transferrin Saturation (TSAT) [ Time Frame: From baseline until week 12 ]
  • Change in reticulocyte count [ Time Frame: From Baseline to week 12 ]
  • Change in haematology parameters [ Time Frame: From baseline and until t= 6 months ]
  • Change in RLS symptoms [ Time Frame: From baseline and until t= 6 months ]

Estimated Enrollment: 100
Study Start Date: June 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Iron isomaltoside 1000
Monofer® 1000 mg IV infusion over 15 minutes
Drug: Iron isomaltoside 1000 (Monofer®)
Other Name: Monofer®
Placebo Comparator: Placebo
0.9 % saline Infusion over 15 min
Drug: Placebo
Other Name: 0.9 % saline

Detailed Description:
At present, clinical efficacy and safety data is available for iron isomaltoside 1000 administered to patients with IDA requiring iron therapy. However, there is a need for clinical efficacy and safety data within iron deficiency without anaemia which is e.g. observed in blood donors. Thus, this study is planned to compare the efficacy and safety of parenteral iron isomaltoside 1000 with placebo in female blood donors with a p-ferritin below 30 µg/L.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women aged ≥ 18 years
  2. First-time donor
  3. P-ferritin < 30 µg/L
  4. Willingness to participate and signed the informed consent form

Exclusion Criteria:

  1. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
  2. Known hypersensitivity to any excipients in the investigational drug products
  3. History of drug related allergies
  4. History of severe asthma
  5. Decompensated liver cirrhosis and hepatitis (defined as ALAT > 3 times upper limit of normal)
  6. Active acute or chronic infections (assessed by clinical judgement supplied with White Blood Cells (WBC) and C-Reactive Protein (CRP))
  7. Rheumatoid arthritis with symptoms or signs of active inflammation
  8. Subjects who are pregnant or nursing. In order to avoid pregnancy, women have to be postmenopausal (at least 12 months since last menstruation), surgically sterile, or use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: intrauterine devices and hormonal contraceptives (contraceptive pills, implants, transdermal patches, vaginal devices, or hormonal injections with prolonged release)
  9. Participation in any other clinical study where the study drug has not passed 5 half-lives prior to the screening
  10. Untreated vitamin B12 or folate deficiency
  11. Treated with other IV or oral iron products within 4 weeks prior to the screening
  12. Treated with Erythropoietin (EPO) within 4 weeks prior to the screening
  13. Any other medical condition that, in the opinion of the Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01895231

Contact: Lars Lykke Thomsen +45 59 48 59 59

Copenhagen, Denmark
Sponsors and Collaborators
Pharmacosmos A/S
Max Neeman
Principal Investigator: Nørgaard RH Blodbanken
  More Information

Responsible Party: Pharmacosmos A/S Identifier: NCT01895231     History of Changes
Other Study ID Numbers: P-Monofer-BD-02
Study First Received: June 26, 2013
Last Updated: March 1, 2016

Additional relevant MeSH terms:
Anemia, Iron-Deficiency
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Ferric Compounds
Trace Elements
Growth Substances
Physiological Effects of Drugs
Hematinics processed this record on September 19, 2017